ARA-290 (Cibinetide) 10mg
Size: 10mg | 99% Purity
M.Wt: ~993
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: Not established
CAS No.: 1208243-50-8
| Purity (HPLC) | >99% |
|---|---|
| Molecular weight | ~993 g/mol |
| CAS number | 1208243-50-8 |
| Synonyms | ARA-290, Cibinetide |
| Solubility | H2O |
| Storage | -20°C / 3 years |
Research reference: View mechanism, literature and identifier graph →
Reconstitution calculator (pre-filled for 10 mg)
Back-in-stock notification
Out of stock. Leave your email and we will notify you when it returns.
HPLC and MS verified by UKAS-accredited laboratories.
Free on orders over £50. Next-day upgrade available.
COA and batch number on every vial.
ARA-290 (Cibinetide) 10mg — research reference material
ARA-290 (Cibinetide) 10mg is supplied by NMChem as a research reference material in a 10mg presentation. Compound class: Erythropoietin-derived 11-residue peptide, characterised in the literature as a tissue-protective peptide. It is supplied strictly for in-vitro laboratory research and is not for human or veterinary use.
Research context
EPO-derived; studied in neuropathic pain, tissue protection. Full mechanism detail, the identifier graph and selected peer-reviewed literature are set out on our ARA-290 research reference. Related compounds in the same research area: BPC-157, TB-500. You can also compare it side by side on our comparison tool.
Presentation
This listing is the 10mg presentation at >99% stated purity, catalogue reference ARA10.
Identifiers
- CAS number: 1208243-50-8
- Molecular weight: ~993 g/mol
- Synonyms: ARA-290, Cibinetide
- Class: Erythropoietin-derived 11-residue peptide
Format & quality
Supplied as 10mg at >99% purity. Identity and purity are characterised by reversed-phase HPLC and mass spectrometry, with a per-batch Certificate of Analysis available on request. This item is a lyophilised powder and requires reconstitution before use; bacteriostatic water is supplied separately, and our reconstitution guide covers volumes and concentrations. Solubility: H2O.
Storage
Store at -20°C, protected from light. Stated shelf life 3 years from date of manufacture. Always confirm against the Certificate of Analysis supplied with your batch.
Research use only — not for human or veterinary use, food, cosmetic or therapeutic application. NMChem supplies this item as a laboratory reference material; no dosing or administration guidance is provided.
Frequently asked questions
What is ARA-290 (Cibinetide) 10mg?
Erythropoietin-derived 11-residue peptide. EPO-derived; studied in neuropathic pain, tissue protection. NMChem supplies it as a research reference material only.
What is the CAS number for ARA-290 (Cibinetide) 10mg?
1208243-50-8. Molecular weight ~993 g/mol.
How should ARA-290 (Cibinetide) 10mg be stored?
At -20°C, protected from light, with a stated shelf life of 3 years. The batch Certificate of Analysis is the controlling document.
Certificate of Analysis
Reconstitution
For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.
Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.
Research literature
Selected peer-reviewed publications from PubMed referencing this compound. Provided for research orientation — not an endorsement of any clinical application. Each citation links to the canonical PubMed record.
-
ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
van Velzen M et al. · Expert opinion on investigational drugs · 2014
PubMed PMID 24555851 -
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.
Zhang W et al. · Peptides · 2016
PubMed PMID 26774587 -
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Al-Onaizi MA et al. · Brain, behavior, and immunity · 2022
PubMed PMID 34343617
You may also need
